Register today to attend Antibody Engineering & Therapeutics Digital Week, our free-to-attend webcast series covering cutting-edge updates on antibody discovery, screening, and selection methods, as well as the latest science designed to accelerate your next-generation therapeutics to market. To learn about sponsorship of future events, contact partners@informaconnectls.com

DAY 1 – May 24th 2022



Engineered Bispecific Antibody for Targeted Inhibition of Tumor Metastasis
9 AM EDT / 2 PM BST / 3 PM CEST

Metastasis is responsible for >90% of deaths related to cancer, yet there is a severe lack of treatments that specifically target stages of the metastatic process. Building on our recent discovery of a synergistic pathway that promotes tumor cell migration independent of proliferation, we developed a novel bispecific antibody that demonstrates remarkable potency and efficacy across preclinical models. Efforts are underway to translate this metastasis-targeted approach to the clinic.

Speaker:

Jamie Spangler, Ph.D.
Assistant Professor, Biomedical Engineering and Chemical & Biomolecular Engineering
Johns Hopkins University

View More Details +

Writing the Future of Biologics to Discover and Optimize Antibodies
10 AM EDT / 3 PM BST / 4 PM CEST

Steven Thomas, presents how Twist Biopharma leverages Twist Bioscience's DNA synthesis technology to rapid end-to-end antibody discovery.

Join the event to learn about Twist Biopharma’s end-to-end antibody discovery and optimization solutions, including highly diverse synthetic naïve antibody phage display libraries, several target class-specific antibody phage display libraries against difficult-to-drug targets, and high-throughput antibody expression service.

Steven Thomas, Twist Biopharma Business Development Manager, will present how Twist Bioscience’s DNA synthesis technology is being applied for rapid end-to-end antibody discovery solutions.

During this digital event you’ll hear about:

  • How Twist Biopharma is building a panel of highly diverse synthetic naïve antibody phage display libraries for difficult-to-drug targets
  • High-throughput antibody expression solutions
  • The Twist Antibody Optimization (TAO) platform for antibody affinity and developability optimization.

Speaker:

Steven Thomas
Business Development Manager
Twist Biopharma, a division of Twist Bioscience

View More Details +

Disrupting the immunotherapy field: A novel platform for targeting chronic diseases
11 AM EDT / 4 PM BST / 5 PM CEST

Vaccines have been some of the most successful modalities for disease management around the globe. However, the application of vaccines to treating chronic diseases has been limited due to the challenge of inducing a safe immune response against self-antigens. Instead, passive immunotherapy approaches, like monoclonal antibodies, have become the means to target disease-associated proteins for chronic diseases. Vaxxinity is disrupting this paradigm by developing a novel platform that triggers a safe and specific antibody response against self-antigen, enabling the use of vaccines to treat chronic diseases. The approach is also cost effective and amenable to wide distribution, allowing broader global reach compared to mAb-based treatments. Currently, Vaxxinity has multiple vaccine candidates in clinical trials, including a phase-I alpha-synuclein vaccine for Parkinson’s disease. This presentation will feature an overview of Sartorius’s advanced bioanalytical solutions for vaccine discovery and development, as well as a deep dive into Vaxxinity’s preclinical path to selecting vaccines, including the novel vaccine for Parkinson’s disease.

Speakers:

David Apiyo, Ph.D.
Senior Manager, Applications
Sartorius

Justin Boyd, Ph.D.
Director of Translational Science
Vaxxinity

View More Details +

DAY 2 – May 25th 2022



Applications of Machine Learning and Informatics in Antibody and Protein Research
9 AM EDT / 2 PM BST / 3 PM CEST

Machine learning has shown its power across all of biology. In this talk I will describe some of the novel machine learning tools we are pioneering in the area of biotherapeutics from computational humanization to accurate rapid structure prediction and virtual high throughput screening.

Speaker:

Charlotte Deane, Ph.D.
Professor of Structural Bioinformatics, Head of the Oxford Protein Informatics Group (OPIG)
University of Oxford, United Kingdom

View More Details +

Optimizing Antibody Discovery & Engineering Workflows with the BioXp System
11 AM EDT / 4 PM BST / 5 PM CEST

What if there was a way to go from digital antibody sequences to transfecting expression constructs for functional characterization in less than a day?

Codex DNA is empowering researchers to do just that. With our BioXp synthetic biology workstation and RapidAMP technology antibody discovery programs can automate their cloning workflow, eliminating days of wait time, bacterial preps, and laborious colony picking.

Join us for this session to learn how Codex DNA’s automated end-to-end synthetic biology solutions can rapidly accelerate antibody discovery pipelines by addressing critical bottlenecks associated with lead candidate gene synthesis, cloning, and scale-up.

Speaker:

Katie Lyons
Director, Field Application Science
Codex DNA

View More Details +

Discovery and Efficient Screening of Fully Human Therapeutic Antibodies for Novel Targets and Epitopes
12 PM EDT / 5 PM BST / 6 PM CEST

The in vivo complexity of B cell differentiation, selection, and affinity maturation cannot be recapitulated in vitro. In this session, we describe the application of several strains of humanized immunoglobulin mice for multiple therapeutic antibody discovery applications and provide proof-of-concept data demonstrating the robust potential of our antibody discovery platform. The combination of in vivo selection in mice and high-throughput screening methodology results in the generation of high affinity antibodies in a much faster timeline compared to traditional antibody discovery methods. Furthermore, challenging targets can be knocked out in these mice to provide hyperimmunity. Thus, our platform facilitates the discovery of novel best-in-class or first-in-class therapeutic antibodies.

Speaker:

Li Hui, MD, PhD
Scientific Director, Antibody Discovery
Biocytogen

View More Details +

REGISTER NOW – Please select the webcast(s) you wish to attend and enter your contact details



Day 1

Day 2